Berry Genomics Co

Berry Genomics Co Financial Debt Ratio

The Financial Debt Ratio of Berry Genomics Co (000710.SZ) as of Nov 5, 2026 is 6.57 %. In the previous year, Financial Debt Ratio was 9.06 % — a change of -27.49% (lower).

Financial Debt Ratio

6.57 %

YoY

-27.49%

Last updated:

Financial Debt Ratio of Berry Genomics Co is 2024 6.57 % . Financial Debt Ratio of Berry Genomics Co was 2023 9.06 % . It decreases by -27.49% lower compared to the previous year.

The Berry Genomics Co Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2016
19.63 CNY
Jan 1, 2017
1.62 CNY
Jan 1, 2019
8.34 CNY
Jan 1, 2020
11.09 CNY
Jan 1, 2021
11.34 CNY
Jan 1, 2022
10.88 CNY
Jan 1, 2023
9.06 CNY
Jan 1, 2024
6.57 CNY
The Berry Genomics Co Financial Debt Ratio history
YEARFinancial Debt RatioYoY
6.57 %-27.49%
9.06 %-16.72%
10.88 %-4.12%
11.34 %+2.28%
11.09 %+32.93%
8.34 %+415.19%
1.62 %-91.75%
19.63 %+3.53%
18.96 %+1.47%
18.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Berry Genomics Co Stock analysis

What does Berry Genomics Co do? Berry Genomics Co., Ltd. generates revenue through basic scientific research services, medical testing services, and the sale of reagents and equipment. The company provides transcriptome sequencing, human whole exome sequencing, and whole genome sequencing for scientific research clients. Medical testing services include tumor genetic testing, genetic disease testing, and reproductive health testing for healthcare providers. Reagent and equipment sales feature the NextSeq CN500 gene sequencer and general reagents for sequencing reactions, targeting research institutions and medical facilities. The primary buyers of basic scientific research services are research institutions requiring advanced sequencing platforms. Medical testing services are purchased by healthcare providers offering diagnostic solutions. Reagent and equipment sales target both research and medical sectors, with the NextSeq CN500 gene sequencer being a key product for high-throughput sequencing needs. The company's revenue streams are segmented by service type, with research services and medical testing forming the core business segments. Berry Genomics' product portfolio includes sequencing platforms, testing reagents, and equipment like the NextSeq CN500 gene sequencer. These products serve research institutions and medical facilities, with medical testing services focusing on tumor, genetic disease, and reproductive health applications. The company's sales strategy emphasizes high-throughput sequencing technology solutions for both scientific and medical markets. Berry Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Berry Genomics Co stock

Financial Debt Ratio of Berry Genomics Co is 6.57 % in 2024.

Financial Debt Ratio of Berry Genomics Co changed from 9.06 % to 6.57 %, representing a -27.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Berry Genomics Co since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Berry Genomics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Berry Genomics Co

All Key Metrics — Berry Genomics Co